Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.
RAHWAY, N.J., May 28, 2024--Merck Announces Third-Quarter 2024 Dividend